Key Takeaways:
Sino Biopharmaceutical (1177.HK) initiated its second Phase 3 clinical trial for the gastric cancer drug Vetricotobat Monoclonal Antibody (LM-302), enrolling the first patient. The Class 1 innovative drug was independently developed by Lixin Pharmaceutical, a wholly-owned subsidiary of the Group, the company announced.
The study, LM302-03-201, combines the CLDN18.2 antibody-drug conjugate with a PD-1 monoclonal antibody for first-line treatment of CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma. It is the world’s first Phase 3 trial for a CLDN18.2 ADC using a chemotherapy-free regimen in this setting.
The trial's success could unlock a major new revenue stream and position Sino Biopharmaceutical at the forefront of chemotherapy-free cancer care. The company's stock rose over 5 percent on the news, reflecting investor optimism about the drug's potential.
Vetricotobat Monoclonal Antibody is an antibody-drug conjugate targeting Claudin18.2 (CLDN18.2), a protein expressed in a high percentage of gastric cancers. This targeted approach aims to deliver a potent anti-cancer agent directly to tumor cells, potentially improving efficacy and reducing side effects compared to traditional chemotherapy.
This trial marks a critical step in developing a new first-line standard of care for a specific subset of gastric cancer patients. Investors will now be watching for interim data readouts and eventual top-line results from the LM302-03-201 study.
This article is for informational purposes only and does not constitute investment advice.
